Literature DB >> 31296552

Correlation of Breath and Blood Δ9-Tetrahydrocannabinol Concentrations and Release Kinetics Following Controlled Administration of Smoked Cannabis.

Kara L Lynch1, Y Ruben Luo2, Shirin Hooshfar2, Cassandra Yun2.   

Abstract

BACKGROUND: Cannabis use results in impaired driving and an increased risk of motor vehicle crashes. Cannabinoid concentrations in blood and other matrices can remain high long after use, prohibiting the differentiation between acute and chronic exposure. Exhaled breath has been proposed as an alternative matrix in which concentrations may more closely correspond to the window of impairment; however, efficient capture and analytically sensitive detection methods are required for measurement.
METHODS: Timed blood and breath samples were collected from 20 volunteers before and after controlled administration of smoked cannabis. Cannabinoid concentrations were measured using LC-MS/MS to determine release kinetics and correlation between the 2 matrices.
RESULTS: Δ9-Tetrahydrocannabinol (THC) was detected in exhaled breath for all individuals at baseline through 3 h after cannabis use. THC concentrations in breath were highest at the 15-min timepoint (median = 17.8 pg/L) and declined to <5% of this concentration in all participants 3 h after smoking. The decay curve kinetics observed for blood and breath were highly correlated within individuals and across the population.
CONCLUSIONS: THC can be reliably detected throughout the presumed 3-h impairment window following controlled administration of smoked cannabis. The findings support breath THC concentrations as representing a physiological process and are correlated to blood concentrations, albeit with a shorter window of detection.
© 2019 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31296552     DOI: 10.1373/clinchem.2019.304501

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation.

Authors:  Tzu-Tang Wei; Mark Chandy; Masataka Nishiga; Angela Zhang; Kaavya Krishna Kumar; Dilip Thomas; Amit Manhas; Siyeon Rhee; Johanne Marie Justesen; Ian Y Chen; Hung-Ta Wo; Saereh Khanamiri; Johnson Y Yang; Frederick J Seidl; Noah Z Burns; Chun Liu; Nazish Sayed; Jiun-Jie Shie; Chih-Fan Yeh; Kai-Chien Yang; Edward Lau; Kara L Lynch; Manuel Rivas; Brian K Kobilka; Joseph C Wu
Journal:  Cell       Date:  2022-04-29       Impact factor: 66.850

2.  Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath.

Authors:  Gregory T Wurz; Michael W DeGregorio
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

3.  Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.

Authors:  Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure
Journal:  Curr Addict Rep       Date:  2019-11-19

4.  A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window.

Authors:  Michael W DeGregorio; Gregory T Wurz; Edward Montoya; Chiao-Jung Kao
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.